Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Brainsway ( (BWAY) ) has provided an update.
On March 11, 2026, BrainsWay reported strong fourth quarter and full‑year 2025 results, with Q4 revenue up 27% year over year to a record $14.5 million and operating income rising to $1.9 million. Full‑year 2025 revenue climbed 27% to $52.2 million, net income surged 161% to $7.6 million, and remaining performance obligations increased 43% to about $70 million, underscoring growing demand and the impact of its shift toward multi‑year lease agreements.
The company highlighted expanding operational scale, shipping a net 95 Deep TMS systems in the quarter and growing its installed base to roughly 1,700 systems while sustaining mid‑70s gross margins. Regulatory and clinical milestones included an FDA label expansion for adolescent major depressive disorder, a new trial for its Deep TMS 360 system in alcohol use disorder, initial insurer coverage for its accelerated SWIFT protocol, and FDA approval of Neurolief’s ProlivRx device, all of which position BrainsWay for continued growth under its 2026 guidance of $66–$68 million in revenue and sharply higher Adjusted EBITDA.
The most recent analyst rating on (BWAY) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on Brainsway stock, see the BWAY Stock Forecast page.
Spark’s Take on BWAY Stock
According to Spark, TipRanks’ AI Analyst, BWAY is a Outperform.
The score is driven primarily by improved profitability, strong cash generation, and a low-leverage balance sheet, reinforced by raised guidance and strong Q3 operating momentum. These positives are tempered by a demanding P/E valuation and technically stretched momentum signals that raise near-term pullback risk.
To see Spark’s full report on BWAY stock, click here.
More about Brainsway
BrainsWay Ltd., listed on Nasdaq and TASE, is a global medical technology company specializing in advanced noninvasive neurostimulation for mental health disorders. Its proprietary Deep Transcranial Magnetic Stimulation platform is FDA‑cleared for major depressive disorder, obsessive‑compulsive disorder, and smoking addiction, targeting patients who require alternative or adjunctive psychiatric treatments.
Average Trading Volume: 196,010
Technical Sentiment Signal: Buy
Current Market Cap: $492.5M
For an in-depth examination of BWAY stock, go to TipRanks’ Overview page.